Department of Pediatrics, Division of Pediatric Endocrinology, Aspirus Steven's Point Hospital, Aspirus Medical Group, Stevens Point, Wisconsin, USA.
Department of Surgery, Division of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Artif Organs. 2022 Aug;46(8):1597-1607. doi: 10.1111/aor.14226. Epub 2022 Mar 17.
Body mass index (BMI) is an important consideration for transplant-eligible left ventricular assist device (LVAD) recipients. LVAD therapy's impact on BMI is unclear. We evaluated BMI changes in patients who underwent LVAD implantation. The association between these patients' BMI and the transplant was studied.
This was a retrospective cohort study of patients who underwent LVAD implantation between January 1, 2012 and December 31, 2018 at our institution. Patients were stratified by preoperative BMI (kg/m ) into four groups: <30, 30-34.9, 34.9-39.9, and ≥40. BMI data were collected at 12 and 6 months prior to implantation, time of implantation, and 3- and 6- months postimplantation.
A total of 107 patients underwent LVAD implantation at our institution. Data were available for 80 patients. Baseline characteristics included a mean age of 56.0 years, 69% male, and a mean implant BMI of 29.9 ± 6.8 kg/m . The mean BMI (kg/m ) for each of the BMI (kg/m ) groups <30, 30-34.9, 35-39.9, and ≥40 (n = 60, 25, 12, and 10, respectively) was 25.1, 32.5, 36.8, and 43.8, respectively. There was no consistent pattern with weight change across differing implant BMIs. No patient with a BMI of <30 gained sufficient weight to impact transplant candidacy. Twenty-three percent of patients with a BMI of 30-34.9 kg/m , 60% of patients with a BMI of 35-39.9 kg/m , and 87.5% of patients with a BMI of ≥40 kg/m had a 6-month BMI potentially affecting transplant.
Associated weight changes during LVAD support may significantly impact transplant candidacy. Higher BMI groups may benefit from multimodal and multidisciplinary targeted weight-loss interventions.
体重指数(BMI)是移植合格的左心室辅助装置(LVAD)受者的重要考虑因素。LVAD 治疗对 BMI 的影响尚不清楚。我们评估了接受 LVAD 植入的患者的 BMI 变化。研究了这些患者的 BMI 与移植之间的关系。
这是一项回顾性队列研究,纳入了 2012 年 1 月 1 日至 2018 年 12 月 31 日期间在我院接受 LVAD 植入的患者。患者根据术前 BMI(kg/m )分为四组:<30、30-34.9、34.9-39.9 和≥40。在植入前 12 个月和 6 个月、植入时和植入后 3 个月和 6 个月收集 BMI 数据。
我院共 107 例患者接受 LVAD 植入,其中 80 例患者的数据可用。基线特征包括平均年龄 56.0 岁,69%为男性,平均植入 BMI 为 29.9±6.8kg/m 。BMI(kg/m )<30、30-34.9、35-39.9 和≥40 组(n=60、25、12 和 10)的平均 BMI(kg/m )分别为 25.1、32.5、36.8 和 43.8。不同植入 BMI 之间的体重变化没有一致的模式。没有 BMI<30 的患者体重增加足以影响移植候选资格。BMI 为 30-34.9kg/m 的患者中 23%、BMI 为 35-39.9kg/m 的患者中 60%、BMI 为≥40kg/m 的患者中 87.5%在 6 个月时 BMI 可能影响移植。
LVAD 支持期间相关体重变化可能显著影响移植候选资格。较高 BMI 组可能受益于多模式和多学科靶向减肥干预措施。